The data are strongly positive and derisk the first-line label expansion. Monitor for sNDA acceptance and FDA priority review status in Q4 2026. The WCLC Presidential Symposium presentation adds peer-reviewed credibility. GSK's oncology pipeline value is incrementally re-rated upward.
Price Chart
Executive Summary
GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing a 94% objective response rate and 90% 12-month progression-free survival. The results support a planned supplemental NDA to the FDA in 2026 to expand the indication from second-line to first-line treatment, which could meaningfully expand the drug's addressable market and peak sales potential.
Key Facts
- 94% objective response rate (ORR) in 94 TKI-naïve patients at 15.2 months median follow-up
- 90% of patients progression-free at 12 months; median PFS not yet reached
- 70% of patients with measurable brain metastases achieved complete intracranial clearance
- Only 1% treatment discontinuation rate due to TRAEs; 11% dose reduction rate
- US regulatory submission (sNDA) for first-line indication planned in 2026
- Drug already FDA-approved for second-line ROS1-positive NSCLC (July 2026)
- Asset acquired via Nuvalent acquisition completed July 2026
Financial Impact
Expanding Jideytro to first-line ROS1-positive NSCLC could address an estimated ~50,000 new annual diagnoses worldwide (2% of NSCLC). First-line label typically captures 2-3x the peak sales of second-line only. No specific revenue figures provided in filing.
Risk Factors
- Regulatory risk: FDA may require additional data or raise concerns about single-arm trial design for first-line approval
- Competitive risk: existing ROS1 TKIs (entrectinib, repotrectinib, taletrectinib) may have overlapping profiles
- Commercial execution risk: GSK must build NSCLC commercial infrastructure against established players
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008318 |
| Document: 0001654954-26-008318-index-headers.html | 0001654954-26-008318 |
| Document: 0001654954-26-008318-index.html | 0001654954-26-008318 |
| Document: 0001654954-26-008318.txt | 0001654954-26-008318 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access